We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CAROLINA LIQUID CHEMISTRIES

Carolina Liquid Chemistries offers a complete line of clinical chemistry analyzers and reagents for use on common pla... read more Featured Products: More products

Download Mobile App




Carolina Liquid Chemistries and Diazyme Enter Into Partnership

By LabMedica International staff writers
Posted on 24 Jan 2023

Carolina Liquid Chemistries, Corp. More...

(CLC, Greensboro, NC, USA) and Diazyme Laboratories, Inc. (San Diego, CA, USA) have entered into a partnership to expand the test menu on the Diazyme DZ-Lite c270 benchtop clinical chemistry analyzer, allowing it to run both special and routine chemistries.

In comparison to using time-consuming and labor-intensive immunoassay platforms, it is more economical to run tests on clinical chemistry analyzers. The DZ-Lite c270 is an advanced benchtop clinical chemistry analyzer with a menu of FDA-cleared, moderately complex, and innovative assays made for clinical laboratories of all sizes. The compact clinical chemistry analyzer supports 1, 2, 3, and 4-part reagent assays and has a throughput of up to 270 tests per hour. The analyzer can be used in all types of clinical laboratory settings such as reference laboratories, hospitals, and physician offices with clinical labs.

Related Links:
Carolina Liquid Chemistries, Corp. 
Diazyme Laboratories, Inc


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.